REGENXBIO Inc. (NASDAQ:RGNX - Get Free Report) was the target of a significant growth in short interest in May. As of May 15th, there was short interest totalling 6,300,000 shares, a growth of 21.9% from the April 30th total of 5,170,000 shares. Currently, 14.6% of the shares of the stock are short sold. Based on an average daily volume of 1,110,000 shares, the short-interest ratio is presently 5.7 days.
REGENXBIO Price Performance
Shares of NASDAQ RGNX traded down $0.05 during midday trading on Wednesday, reaching $10.08. 690,256 shares of the company traded hands, compared to its average volume of 904,943. The company has a market cap of $505.61 million, a price-to-earnings ratio of -2.00 and a beta of 1.11. REGENXBIO has a 52 week low of $5.04 and a 52 week high of $15.36. The stock has a 50-day moving average price of $7.97 and a 200 day moving average price of $7.94.
REGENXBIO (NASDAQ:RGNX - Get Free Report) last posted its earnings results on Monday, May 12th. The biotechnology company reported $0.12 EPS for the quarter, missing the consensus estimate of $0.41 by ($0.29). The business had revenue of $89.01 million during the quarter, compared to the consensus estimate of $105.35 million. REGENXBIO had a negative return on equity of 70.65% and a negative net margin of 283.19%. As a group, analysts expect that REGENXBIO will post -4.84 EPS for the current year.
Analyst Ratings Changes
A number of equities research analysts recently weighed in on RGNX shares. Leerink Partners set a $24.00 price target on REGENXBIO in a report on Tuesday, March 18th. The Goldman Sachs Group decreased their target price on shares of REGENXBIO from $14.00 to $12.00 and set a "neutral" rating on the stock in a research report on Thursday, April 17th. Chardan Capital restated a "buy" rating and set a $52.00 price objective on shares of REGENXBIO in a report on Thursday, March 20th. Raymond James initiated coverage on REGENXBIO in a research note on Friday, February 7th. They issued an "outperform" rating and a $27.00 target price for the company. Finally, HC Wainwright decreased their price target on shares of REGENXBIO from $36.00 to $34.00 and set a "buy" rating on the stock in a report on Monday, March 17th. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to MarketBeat, the company presently has an average rating of "Moderate Buy" and an average price target of $31.63.
View Our Latest Research Report on RGNX
Insider Activity
In related news, Director Kenneth T. Mills sold 20,602 shares of the company's stock in a transaction that occurred on Monday, May 12th. The shares were sold at an average price of $7.91, for a total transaction of $162,961.82. Following the sale, the director now directly owns 475,103 shares of the company's stock, valued at $3,758,064.73. This represents a 4.16% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Company insiders own 12.79% of the company's stock.
Institutional Inflows and Outflows
Several large investors have recently bought and sold shares of the company. Acadian Asset Management LLC acquired a new position in REGENXBIO during the first quarter valued at approximately $1,123,000. Jane Street Group LLC lifted its stake in REGENXBIO by 151.1% in the 1st quarter. Jane Street Group LLC now owns 414,067 shares of the biotechnology company's stock valued at $2,961,000 after acquiring an additional 249,156 shares in the last quarter. Exome Asset Management LLC bought a new position in REGENXBIO in the first quarter valued at approximately $2,898,000. AQR Capital Management LLC raised its stake in shares of REGENXBIO by 2,247.7% during the 1st quarter. AQR Capital Management LLC now owns 620,595 shares of the biotechnology company's stock worth $4,437,000 after purchasing an additional 594,161 shares in the last quarter. Finally, ADAR1 Capital Management LLC boosted its holdings in shares of REGENXBIO by 86.4% in the 1st quarter. ADAR1 Capital Management LLC now owns 350,352 shares of the biotechnology company's stock valued at $2,505,000 after buying an additional 162,423 shares during the last quarter. Institutional investors and hedge funds own 88.08% of the company's stock.
REGENXBIO Company Profile
(
Get Free Report)
REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapies that deliver functional genes to cells with genetic defects in the United States. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus gene delivery platform. The company's products in pipeline includes ABBV-RGX-314 for the treatment of wet age-related macular degeneration, diabetic retinopathy, and other chronic retinal diseases; and RGX-202, which is in Phase I/II clinical trial for the treatment of Duchenne muscular dystrophy.
Featured Stories
Before you consider REGENXBIO, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and REGENXBIO wasn't on the list.
While REGENXBIO currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering what the next stocks will be that hit it big, with solid fundamentals? Enter your email address to see which stocks MarketBeat analysts could become the next blockbuster growth stocks.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.